Stock ERIS ERIS LIFESCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Market Closed - Bombay S.E.
Other stock markets
 11:11:41 03/05/2024 BST 		5-day change 1st Jan Change
867 INR -2.68% Intraday chart for Eris Lifesciences Limited -2.86% -4.78%
04-03 Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
03-15 Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business
MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion
MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics
MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million
RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.
CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals
MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.
CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026
CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.
CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns
RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics
CI
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units
AQ
Indian shares set to open higher tracking Asian peers
RE
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024
CI
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ERIS Stock
  4. ERIS Stock
  5. News Eris Lifesciences Limited